Teva said they see opportunity for laquinimod as an adjuvant therapy especially for patients who have relapsed. Currently, and assuming no major surprises with BG-12, I think Roy is correct in #msg-68711531 saying
Even in the best-case scenario for Teva, it will be a day late and a dollar short.
Market Data 
Markets 
AI
